MRK · 10-Q · 2026Q2 · Full report

Guidance and Outlook

Merck & Co., Inc. · 2026-08-07 · Importance 57 · Surprise 50

Merck expects alliance revenue to decline for full-year 2026 as Adempas loses U.S. market exclusivity. The company expects U.S. Bridion sales to decline following loss of market exclusivity in July 2026 and plans to discontinue U.S. sales in 2027 as generic supply stabilizes. Merck also expects Lagevrio sales to continue declining during 2026 and is working with FDA on U.S. product disposition by June 29, 2027 after the HHS COVID-19 EUA declaration terminates.